Check the pulse of biotech IT in Boston
Biotech computing folks from around the world descended on Boston this week, and the FierceBiotech IT team was among them. Check out the slide show.
Fierce's Top 10 Biotech Techies
Tech-savvy scientists can help pull the biopharma industry out of the proverbial muck. FierceBiotech IT has selected a list of 10 innovators who are challenging the status quo in their fields.
TOP HEADLINES
Editor's Corner
Join a live Twitter chat with Medidata's Glen de Vries
De Vries and I have spoken several times over the past year about how cloud computing and other innovations are changing the way clinical trials data and operations are managed. We recently agreed to host one such chat in the Twitterverse.
Startup Knode takes off with pharma fuel
Knode has sprung to life with web-based software to enable life sciences stakeholders to hunt for top experts.
Piramal banks on pharma's data binging in $635M buyout of Decision Resources
Sold on the growing need for data in biopharma, India's Piramal Healthcare has scooped up Decision Resources Group in deal valued at about $635 million.
UPDATED: Mobile apps could rival pharma's crown jewels
As we pack more data about our health into mobile devices, pharma companies could face a new competitive threat to their drugs: Mobile health apps.
NIH pumps $6M into DNA analysis for Alzheimer's plan
As GenomeWeb reports, the National Institutes of Health's National Institute on Aging has heeded the president's call for action and awarded up to $6 million for three projects that aim to analyze DNA sequencing data related to Alzheimer's.
UPDATED: BioClinica chief touts Microsoft ties in Q1 report
BioClinica ($BIOC) capitalized on the compatibility of its clinical trials software with Microsoft ($MSFT) technology and boosted revenue and income during the first quarter that ended March 31, the company said last week.
From Our Sister Sites
The deal comes amid rapid business expansion at Decision Resources, which provides web-based research tools, predictive analytics and other services to drugmakers and other healthcare stakeholders.
PA alleges that J&J oversold the drug's benefits while underselling the risks.
POPULAR COMMENT THREADS